Cell Therapy for Coronary Heart Disease

• Status: Terminated
• Trial end date: 2005-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Impaired contractile function after a heart attack and due to coronary heart disease is a major cause of "heart failure" limiting quality of life and prognosis, which cannot be prevented even with optimal standard therapy.

The aim of the current trial is to investigate whether infusion of progenitor cells into the coronary artery supplying the most dyskinetic left ventricular area may improve left ventricular contractile function, compared to no cell infusion in the control group, in patients with old (>= 3 months) myocardial infarction.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johann Wolfgang Goethe University Hospital

Criteria

Inclusion Criteria:

• Patients aged 18 to 80

• Patients post-myocardial infarction (> 3 months old) or with diffuse ischemic CHD

• Signed informed consent

Exclusion Criteria:

• Existing neoplastic disease or signs of tumor recurrence within the last 5 years

• Active infection

• Active internal bleeding

• Stroke within the past 2 years

• Surgery or trauma within the past two months

• Uncontrolled hypertension over 160/100

• Arteriovenous malformations or aneurysms

• HIV infection

• Signs of significant kidney or liver failure (creatinine > 2.0 mg/dL, GOT > 2 x upper standard value)

• Thrombopenia (< 100,000)

• Anemia (hemoglobin < 8.5 g/dL)

• Mental retardation

• Participation in another clinical study

• Women of childbearing age

• Chronic inflammatory disease